I was in Paris this week in the building of the Rare Disease Alliance, an association helping patients affected by a rare disease. The association lend their space to Neovacs, a biotech company from Paris, which was organising a gathering of experts of lupus.

neovacs_logo_immunotherapy_lupus_stellarLupus is one of the most common rare disease and affects more than 5 million people worldwide. This meet-up was a good opportunity for me to talk with Prf. Jean Sibilia,  Head of the National Reference Centre for Systemic Autoimmune Diseases and Miguel Sieler, CEO of Neovacs which develops a drug candidate against this disease.

Learn more in the video below!

More on Neovacs in these articles from Labiotech.eu:

Want to know more?

We’re preparing a special article to be published for World Lupus Day on May 10th. Stay tuned on Labiotech.eu!


Previous post

How the UK is Engineering Bacteria to produce Propane for Greener Fuels

Next post

Stem cell Biotech gets €26M to Start-off Gene Therapy Development for Children

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.